These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2400399)

  • 1. Effect of N-methylation on the modulation by synthetic peptides of the activity of the complement-factor-B-derived serine proteinase CVFBb.
    Berkovich A; O'Keefe MC; Hensley P; Caporale L
    Biochem J; 1990 Sep; 270(2):531-7. PubMed ID: 2400399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leupeptin inhibits the C3/5 convertase CVFBb of the complement system.
    Caporale LH
    Biochim Biophys Acta; 1981 Jul; 660(1):151-3. PubMed ID: 6974008
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
    von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
    Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human complement proteins D, C2, and B. Active site mapping with peptide thioester substrates.
    Kam CM; McRae BJ; Harper JW; Niemann MA; Volanakis JE; Powers JC
    J Biol Chem; 1987 Mar; 262(8):3444-51. PubMed ID: 3546307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling the enzymatic properties and inhibition of human complement factor B.
    Le GT; Abbenante G; Fairlie DP
    J Biol Chem; 2007 Nov; 282(48):34809-16. PubMed ID: 17921140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and activation of complement components C2 and factor B.
    Gagnon J
    Philos Trans R Soc Lond B Biol Sci; 1984 Sep; 306(1129):301-9. PubMed ID: 6149575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved fluorogenic substrate for the alternative complement pathway C3/5 converting enzyme CVFBb.
    Gutierrez JC; Götze O; Caporale LH
    Biochim Biophys Acta; 1983 May; 744(3):276-80. PubMed ID: 6552199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides.
    Lesavre P; Gaillard MH; Halbwachs-Mecarelli L
    Eur J Immunol; 1982 Mar; 12(3):252-4. PubMed ID: 6920299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies.
    Burger R; Deubel U; Hadding U; Bitter-Suermann D
    J Immunol; 1982 Nov; 129(5):2042-50. PubMed ID: 6181157
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthetic peptides and fluorogenic substrates related to the reactive site sequence of Kunitz-type inhibitors isolated from Bauhinia: interaction with human plasma kallikrein.
    Oliva ML; Santomauro-Vaz EM; Andrade SA; Juliano MA; Pott VJ; Sampaio MU; Sampaio CA
    Biol Chem; 2001 Jan; 382(1):109-13. PubMed ID: 11258660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages.
    Beuscher HU; Brade V
    Immunology; 1986 Aug; 58(4):545-51. PubMed ID: 3089917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships for substrate-based inhibitors of human complement factor B.
    Ruiz-Gómez G; Lim J; Halili MA; Le GT; Madala PK; Abbenante G; Fairlie DP
    J Med Chem; 2009 Oct; 52(19):6042-52. PubMed ID: 19743866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial sequence of human complement component factor B: novel type of serine protease.
    Christie DL; Gagnon J; Porter RR
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4923-7. PubMed ID: 6776529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of the primary substrate specificity pocket of complement factor B. Asp(226) is a major structural determinant for p(1)-Arg binding.
    Xu Y; Circolo A; Jing H; Wang Y; Narayana SV; Volanakis JE
    J Biol Chem; 2000 Jan; 275(1):378-85. PubMed ID: 10617628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
    Sundsmo JS; Wood LM
    J Immunol; 1981 Sep; 127(3):877-80. PubMed ID: 6911148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.